|
|
|
|
| LEADER |
03215nam a2200877Ia 4500 |
| 001 |
10-1093-cid-ciab465 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 10584838 (ISSN)
|
| 245 |
1 |
0 |
|a Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
|
| 260 |
|
0 |
|b Oxford University Press
|c 2022
|
| 300 |
|
|
|a 4
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1093/cid/ciab465
|
| 520 |
3 |
|
|a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA). © 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
|
| 650 |
0 |
4 |
|a 2019-nCoV Vaccine mRNA-1273
|
| 650 |
0 |
4 |
|a adult
|
| 650 |
0 |
4 |
|a Antibodies, Viral
|
| 650 |
0 |
4 |
|a antibody production
|
| 650 |
0 |
4 |
|a antigen
|
| 650 |
0 |
4 |
|a Article
|
| 650 |
0 |
4 |
|a blood sampling
|
| 650 |
0 |
4 |
|a clinical article
|
| 650 |
0 |
4 |
|a clinical trial
|
| 650 |
0 |
4 |
|a controlled study
|
| 650 |
0 |
4 |
|a coronavirus disease 2019
|
| 650 |
0 |
4 |
|a coronavirus nucleocapsid protein
|
| 650 |
0 |
4 |
|a coronavirus spike glycoprotein
|
| 650 |
0 |
4 |
|a COVID-19
|
| 650 |
0 |
4 |
|a COVID-19
|
| 650 |
0 |
4 |
|a COVID-19 Vaccines
|
| 650 |
0 |
4 |
|a disease severity
|
| 650 |
0 |
4 |
|a elasomeran
|
| 650 |
0 |
4 |
|a genetics
|
| 650 |
0 |
4 |
|a health care personnel
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a human tissue
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a immune responses
|
| 650 |
0 |
4 |
|a immunoassay
|
| 650 |
0 |
4 |
|a immunoglobulin A
|
| 650 |
0 |
4 |
|a immunoglobulin A
|
| 650 |
0 |
4 |
|a Immunoglobulin A
|
| 650 |
0 |
4 |
|a immunoglobulin blood level
|
| 650 |
0 |
4 |
|a immunoglobulin G
|
| 650 |
0 |
4 |
|a immunoglobulin M
|
| 650 |
0 |
4 |
|a limit of detection
|
| 650 |
0 |
4 |
|a mrna 1273
|
| 650 |
0 |
4 |
|a mRNA vaccine
|
| 650 |
0 |
4 |
|a pilot study
|
| 650 |
0 |
4 |
|a prevention and control
|
| 650 |
0 |
4 |
|a protein blood level
|
| 650 |
0 |
4 |
|a receptor binding
|
| 650 |
0 |
4 |
|a RNA translation
|
| 650 |
0 |
4 |
|a SARS-CoV-2
|
| 650 |
0 |
4 |
|a SARS-CoV-2 antigens
|
| 650 |
0 |
4 |
|a Severe acute respiratory syndrome coronavirus 2
|
| 650 |
0 |
4 |
|a spike
|
| 650 |
0 |
4 |
|a Spike Glycoprotein, Coronavirus
|
| 650 |
0 |
4 |
|a spike protein, SARS-CoV-2
|
| 650 |
0 |
4 |
|a virus antibody
|
| 650 |
0 |
4 |
|a virus neutralization
|
| 650 |
0 |
4 |
|a virus nucleocapsid
|
| 650 |
0 |
4 |
|a virus spike
|
| 650 |
0 |
4 |
|a virus spike protein
|
| 650 |
0 |
4 |
|a young adult
|
| 700 |
1 |
0 |
|a Baden, L.R.
|e author
|
| 700 |
1 |
0 |
|a Cheng, C.-A.
|e author
|
| 700 |
1 |
0 |
|a Desjardins, M.
|e author
|
| 700 |
1 |
0 |
|a Li, X.
|e author
|
| 700 |
1 |
0 |
|a Novack, L.
|e author
|
| 700 |
1 |
0 |
|a Ogata, A.F.
|e author
|
| 700 |
1 |
0 |
|a Powell, M.
|e author
|
| 700 |
1 |
0 |
|a Senussi, Y.
|e author
|
| 700 |
1 |
0 |
|a Sherman, A.C.
|e author
|
| 700 |
1 |
0 |
|a Von, S.
|e author
|
| 700 |
1 |
0 |
|a Walt, D.R.
|e author
|
| 773 |
|
|
|t Clinical Infectious Diseases
|
